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Gregory L. Moneta, MD, Section EditorA Randomized Trial of Rosuvastatin in the Prevention of Venous
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Conclusion: In healthy persons, rosuvastatin reduces the occurrence of
symptomatic venous thromboembolism.
Summary: Some observational studies have suggested a decreased risk
of venous thromboembolism (VTE) in patients treated with statins (Ann
Intern Med 2000;132:689-96, and Arch Intern Med 2001;161:1405-10).
Other studies, however, have shown no association between the use of
statins and venous thrombosis (Br J Clin Pharm 2008;67:99-109). The
current study is a subanalysis of the Justification of the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
JUPITER examined whether or not rosuvastatin, 20 mg daily, compared
with placebo, would reduce the rates of first major cardiovascular events.
The occurrence of VTE was a protocol-specified secondary end point of
JUPITER.
The study randomly assigned 17,802 apparently healthy men and
women to receive rosuvastatin, 20 mg daily, or placebo. Patients were
monitored for first occurrence of pulmonary embolism (PE) or deep venous
thrombosis (DVT). Data were analyzed on an intention to treat basis.
Median follow-up was 1.9 years (maximum, 5.0 years). Symptomatic VTE
occurred in 94 participants: 60 in the placebo group and 34 in the rosuva-
statin group. Rates of VTE were 0.18/100 person-years in the rosuvastatin
group (hazard ratio [HR], 0.57; 95% confidence interval (CI), 0.37-0.86; P
 .007) and 0.32/100 person-years in the placebo group. For unprovoked
VTE, that is, VTE occurring in the absence of known malignant conditions,
surgery, trauma, or hospitalization, rates were 0.10/100 person-years in the
rosuvastatin group and 0.17/100 person-years in the placebo group (HR,
0.61, 95% CI, 0.35-1.09; P .09). Rates for provoked VTEwere 0.08/100
person-years in the rosuvastatin group and 0.16/100 person-years in the
placebo group (HR, 0.52; 95% CI, 0.28-0.96; P .03). Rates of PE did not
differ between the rosuvastatin group and placebo groups. Rates of DVT
were 0.09/100 patient-years in the rosuvastatin group and 0.20/100 pa-
tient-years in the placebo group (HR, 0.45; 95% CI, 0.25-2.79; P  .004).
There were no differences between treatment groups in the rates of bleeding
episodes.
Comment:Venous and arterial thromboses carry some risk factors that
are shared. The nature and extent of these shared pathways and whether
demonstrated efficacy for prevention of one condition can translate to the
other is controversial. This study suggests another potentially important
pleiotropic effect of statin medications. This study was prospective and
double-blind, and prespecified VTE as an end point, and therefore has
considerable strength. However, the study only occurred in patients who
were thought to be healthy, there is relatively limited follow-up, and it does
not allow for evaluation of the relationship between the dose of statin and
risk of VTE. Future data, particularly on the ability of statin medications to
decrease VTE in higher-risk patients will be interesting.
Associations of Borderline and Low Normal Ankle-Brachial Index
Values With Functional Decline at 5-Year Follow-Up. The WALCS
(Walking and Leg Circulation Study)
McDermott MM, Guralnik JM, Tian L, et al. J Am Coll Cardiol 2009;53:
1056-62.
Conclusion: A “low-normal” ankle-brachial index (ABI) has an in-
creased incidence of late mobility loss compared with a normal ankle-
brachial index (ABI).
Summary: An estimated 8 million persons in the United States have
peripheral arterial disease (PAD) of the lower extremities. PAD is defined as
an ABI 0.9. These patients have increased rates of functional decline and
greater functional impairment than those without PAD. In this study, the
authors sought to ascertain the possible association between functional
decline and the presence of borderline or low-normal ABI values. They
hypothesized that patients with borderline or low-normal baseline ABI
values would have slower rates of functional decline than PAD patients and
that functional decline would be greater than in persons with a normal ABI.
Participants in this study were part of theWalking and Leg Circulation Study
(WALCS) study to identify predictors of functional decline in persons with
and without PAD. Of the 666 study participants, 412 had PAD. Participants
were categorized as having severe PAD (ABI 0.5), moderate (ABI 0.5-
0.69), mild (ABI 0.7-0.89), borderline to low-normal (ABI 0.9-1.09), or
normal without PAD (ABI 1.10-1.30). Mobility loss was defined as loss of
ability to walk one-quarter mile or walk up and down one flight of stairs
without assistance in individuals who did not have baseline mobility impair-ment. Participants unable to walk for 6 minutes were defined as stopping
during a 6-minute walk test during a follow-up examination when they were
able to complete the 6-minute walk test on their initial study. Outcomes
were assessed annually for 5 years, and results were adjusted for age, race,
comorbidities, gender, and other confounders.
Hazard ratios for mobility loss according to ABI category were severe
PAD, 4.16 (95% confidence interval [CI], 1.58-10.92); moderate PAD,
3.82 (95% CI, 1.66-8.81); mild PAD, 3.22 (95% CI, 1.43-7.21); borderline
PAD, 3.07 (95% CI, 1.21-7.84); and low-normal PAD, 2.61 (95% CI,
1.08-6.32; P trend  .0018). Associations for becoming unable to walk for
6 minutes continuously were similar (P trend .0001).
Comment: ABI values 0.9 are both specific and sensitive for a
diagnosis of PAD. The findings here suggest that patients with low-normal
or borderline ABI values have higher rates of functional decline than patients
with truly normal ABIs (1.1 to 1.3). These results may reflect a higher rate of
progression of lower extremity atherosclerosis among patients with low-normal
and borderline ABI values. Alternatively, low-normal and borderline ABI values
may be markers for atherosclerosis elsewhere or other comorbidities that can
influence mobility and performance on the 6-minute walk test. What is clear is
that functional impairment is associated with even very mild PAD.
Diagnostics of “non-acute” vascular prosthesis infection using 18F-
FDG PET/CT: our experience with 96 prostheses
Spacek M, Belohlavek O, Votrubova J, et al. Euro J Nuc Med Mol Imaging
2009;36:850-8.
Conclusion: Positron emission tomography (PET)/computed to-
mography (CT) imaging is an excellent diagnostic modality for suspected
vascular prosthetic graft infection (VPGI).
Summary: The use of hybrid imaging technology is increasing; in
particular, the combination of PET and CT using 18F-fluorodeoxyglucose
(18F-FDG) has become a well-accepted tool for diagnosis of cancer. Hybrid
technologies provide a combination of high spatial resolution morphologic
CT data with functional PET data in one image. Tissues with highmetabolic
activity are characterized by cumulative FDG uptake. 18F-FDG PET also
has a high sensitivity for diagnosis of infection and inflammation. The
purpose of this study was to test the accuracy of FDG PET/CT in the
diagnosis of VPGI. The authors sought to evaluate this technology in a set of
patients with possible low-grade VPGIs and nonacute presentations. They
performed PET/CT prospectively in 76 consecutive patients (52 men, 24
women) with 96 prosthetic grafts with suspected VPGI. Studies were
performed between May 2004 and May 2007. Patients were recruited from
a large tertiary vascular surgery referral center in Czechoslovakia. The
presence and intensity of focal and diffuse FDG uptake was analyzed from
the PET/CT scans. Also analyzed was the presence of an anastomotic
aneurysm, presence of an irregular boundary of infiltration, combinations of
these, and an uptake ratio between the graft and blood background.
PET/CT findings were then compared with operative and histopathologic
findings or clinical follow-up 6 months.
Of the assessed parameters, only an irregular graft boundary and focal
FDG uptake were significant predictors of VPGI. If focal intense FDG
uptake and an irregular boundary of the lesion were both present on the CT
scan, this correlated with a 97% probability of a VPGI. Smooth lesion bound-
aries and no focal FDG uptake predicted a probably of VPGI of 5%. When
there was inhomogeneous focal FDG uptake (18 of the 96 patients), an
irregular boundary on the CT scan aided decision making with a probability of
28% for a VPGI if the boundary was smooth vs a probability of 77% for VPGI if
the boundary was irregular. In this study, 57.3% of the prosthetic grafts evalu-
ated (55 of 96) eventually had a clinical diagnosis of VPGI. The presence of
intense focal FDG uptake was specific for VPGI in 92.7% of prostheses and had
a very high positive predictive value of 93.5% for predicting VPGI.
Comment: Low-grade infection of a prosthetic graft can be difficult to
diagnose. The authors’ technique of combining FDG PET/CT provides
anatomic, functional, andmetabolic data in a single session. CT scanning has
only about 55% sensitivity with respect to detecting low-grade VPGI. The
hybrid imaging technique presented here appears to offer a substantial
improvement over CT scanning alone in the detection of low-grade VPGI.
Improved Long-Term Survival After Abdominal Aortic Aneurysm
Repair
Mani K, Björck M, Lundkvist J, et al. Circulation 2009;120:201-11.Conclusion: Despite a change in case-mix toward older patients with
increased comorbidity, long-term survival after repair of an intact abdominal
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